Seeing the Quarter Clearly: SGHT’s Q2 2026 Revenue Upbeat, Guidance Adjusted as IDE Reaches New Highs

Executive snapshot

Sight Sciences, ticker SGHT, delivered a Q2 2026 that leans into revenue growth and a recalibration of cost expectations rather than a tidy EPS figure. The company highlighted a second-quarter revenue of $23.4 million, up 20% from $19.6 million in the prior-year quarter. Interventional Glaucoma (IG) revenue totaled $20.7 million, an 8% rise year over year, while Interventional Dry Eye (IDE) revenue stood at a record $2.7 million, marking a dramatic 704% increase versus the second quarter of 2025.

On the balance sheet and cash flow side, cash and cash equivalents were $79.8 million as of June 30, 2026. Cash usage in the quarter was $5.2 million, a 28% improvement versus the same period last year. Notably, the quarter included non-recurring items totaling a $5.4 million litigation success fee, offset by $1.6 million in tariff refunds. Excluding these one-time items, cash usage was a lean $1.4 million, an 81% year-on-year improvement.

The company also disclosed a positive development in IDE patient access: following an update to Medicare pricing guidance for CPT code 0563T, estimated IDE patient lives with access to reimbursement expanded from roughly 10.4 million to 14.5 million (an increase of about 4.1 million lives in Q2 2026).

Guidance and market signals

Management raised its revenue forecast for full-year 2026, signaling confidence in continued top-line momentum. At the same time, the company reduced adjusted operating expense guidance, indicating an emphasis on profitability discipline as it scales. This combination—higher revenue expectations paired with tighter controllable costs—tends to get the attention of investors evaluating EPS trajectories, even when an explicit EPS figure isn’t disclosed in the press release.

In terms of analyst discourse, readers will likely scan for an EPS consensus and any mention of earnings surprise versus Street expectations. The current release does not present an EPS result or a quantified earnings surprise, so the next quarterly print will be the moment to calibrate whether the revenue strength translates into a cleaner bottom line, or if the gross-to-operating expense mix remains the swing factor.

Recent highlights and what they imply

• Revenue growth leadership: The two core segments—IG and IDE—continue to diverge in pace. IG growth remains healthy at 8% YoY, while IDE shows triple-digit growth, pointing to a potential future mix shift as reimbursement dynamics evolve.
• Cash runway and one-time items: The quarterly cash burn improves materially when removing non-recurring fees. The litigation success fee, while a one-off, underscores the volatile elements that can swing quarterly cash flow without changing underlying operating momentum.
• Reimbursement tailwinds appear material: The 4.1 million additional IDE lives brought into alignment with Medicare pricing for CPT 0563T expand access and potential utilization, a driver that could sustain IDE volumes if payer dynamics remain favorable.
• Strategic posture: By dialing back adjusted Opex while pushing for higher revenue, the company signals an intent to reach a more scalable cost structure as it monetizes its interventional technologies across glaucoma and related ocular care and expands patient access.

What it could portend for the sector

The eye-care technology ecosystem often rewards durable top-line growth, measurable adoption, and a clear path to improving operating margins as volumes scale. SGHT’s Q2 results feed into a broader narrative about payer-aligned pricing and rapid expansion of reimbursable patient lifespans—a dynamic that, if sustained, could pressure peers to articulate similar access- and revenue-focused milestones. In markets where disposition toward capital efficiency matters, investors may reward a trajectory that blends rising revenue with more disciplined cost economics, even amid one-off items.

Industry peers eyes will also watch the cadence of reimbursement policy updates, particularly around CPT codes that unlock IDE patient access. A durable improvement in IDE volumes, supported by favorable pricing, could become a de facto growth lever for comparable ophthalmology interventional companies, beyond just SGHT.

Bottom-line read

In Matt Levine-like fashion: the quarter doesn’t declare a problem so much as it broadcasts a strategic pivot. Revenue momentum is real, the balance sheet looks stable, and the cost structure is being tuned for scale. The absence of a disclosed EPS in this release isn’t a flaw so much as a byproduct of a narrative centered on revenue mix and reimbursement-driven access. If the revenue forecast holds and the company maintains its cost discipline, SGHT could convert the Q2 lift into sustainable earnings power—at least enough to tempt observers to think about earnings surprises in a future print.

Key takeaways

1. SGHT reports solid revenue growth across its IG and IDE segments, with IDE posting an unusually strong quarterly trajectory.
2. The revenue forecast upgrade and reduced adjusted Opex guidance suggest a shift toward a more scalable profitability profile, even as one-off items color quarterly cash flow.
3. Expanded IDE patient access due to pricing alignment with Medicare pricing signals potential mid-term volume upside, contingent on ongoing payer and policy developments.
4. In the absence of a disclosed EPS number in this release, investors will look to the next quarterly print for an EPS consensus and any explicit earnings surprise relative to Street estimates.
5. Sector peers may respond to SGHT’s mix shift and reimbursement sensitivity by emphasizing payer dynamics and scalable cost control as levers for durable growth.